Aflibercept-Based and Bevacizumab-Based Second Line Regimens in Patients with Metastatic Colorectal Cancer: Propensity Score Weighted-Analysis from a Multicenter Cohort

Both aflibercept and bevacizumab-based regimens are available II-line treatment options for patients with metastatic colorectal cancer (mCRC). However, no head-to-head trials established the optimal anti-angiogenic strategy for this setting. We launched a multicenter, retrospective, observational st...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical colorectal cancer 2025-01
Hauptverfasser:	Lucchetti, Jessica, Angotti, Lorenzo, Parisi, Alessandro, Basso, Michele, Polito, Mariam Grazia, Zoratto, Federica, Di Giacomo, Emanuela, Nitti, Daniele, Minelli, Alessandro, Salvatore, Lisa, Calegari, Maria Alessandra, Lo Prinzi, Federica, Gemma, Donatello, Signorelli, Carlo, Veroli, Margherita, Anghelone, Annunziato, Galbato Muscio, Luca, Di Cocco, Barbara, Trombetta, Giorgio, Morelli, Cristina, Schietroma, Francesco, Vincenzi, Bruno, Cortellini, Alessio, Tonini, Giuseppe
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-angiogenic Chemotherapy II-line mCRC VEGF
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!